Novo Nordisk
Mentioned in 45 analyzed podcast episodes across 10 shows
A Danish pharmaceutical company and global leader in GLP-1 weight loss and diabetes medications (Ozempic, Wegovy), commanding significant market share in a rapidly evolving trillion-dollar market. Novo Nordisk has faced substantial stock volatility due to pricing pressures, disappointing trial results for experimental obesity drugs relative to competitors like Eli Lilly, litigation with telehealth companies over compounded versions, and announced price cuts of up to 50% beginning in 2027. The company also maintains critical infrastructure control, including 74% of global insulin supply, making it a frequent topic in financial, healthcare, and trade-related podcast discussions.
Mentioned On
Episode Mentions
Armstrong & Getty On Demand · Apr 2, 2026
Oh My God I Hate The Left
“Manufacturer of Wegovy pill, competitor to Mounjaro with more restrictive dosing requirements”
PBS News Hour - Full Show · Apr 1, 2026
April 1, 2026 - PBS News Hour full episode
“Competitor in weight loss pharmaceutical market with Uygovy pill, which Foundayo follows as second daily oral medication”
Mad Money w/ Jim Cramer · Apr 1, 2026
Mad Money w/ Jim Cramer 4/1/26
“Competitor in GLP-1 weight loss pill market with slightly better efficacy but inferior convenience compared to Lilly's Foundail”
CNBC's "Fast Money" · Apr 1, 2026
Markets Rally Ahead of Trump’s Iran Address… And Fading The Bounce 4/1/26
“Oral Wegovy pill shows 17% weight loss efficacy, launched earlier in 2026, competing with Eli Lilly's Fondayo in GLP-1 market”
TBPN · Mar 28, 2026
Novartis Buys Excellergy for $2B, Anthropic Vs. Pentagon, The Mansion Section | Diet TBPN
“Pharmaceutical company using AI agents to shorten clinical trials”
TBPN · Mar 19, 2026
FULL INTERVIEW: Mark Cuban on Robots, AI, Self-Driving, and Advice to Students
“Mentioned alongside Eli Lilly for smart direct-to-patient GLP-1 strategies”
NPR News Now · Mar 5, 2026
NPR News: 03-05-2026 5PM EST
“GLP-1 drug Ozempic discussed in study showing reduced addiction risk in diabetes patients”
Danny Jones Podcast · Feb 27, 2026
#374 - Ex-Pharma Insider Exposes the $368 Billion Health Insurance Scam | Brigham Buhler
“GLP-1 manufacturer sued compounding pharmacies; lobbies FDA against peptide accessibility”
Marketplace All-in-One · Feb 26, 2026
What it costs to become an Olympian or Paralympian
“Danish pharmaceutical company cutting Ozempic and Wegovy prices by up to 50% amid FDA regulatory pressure on compounders”
Marketplace Morning Report · Feb 26, 2026
What it costs to become an Olympian or Paralympian
“Danish pharma company cutting Ozempic and Wegovy prices by up to 50% after Trump administration pricing deals; stock down 40%”
CNBC's "Fast Money" · Feb 24, 2026
Growing AI Warnings… And Opportunities in Private Credit & Real Estate 2/24/26
“Cutting Ozempic and Wegovia prices by 50% starting next year; stock down 3% on announcement”
NPR News Now · Feb 24, 2026
NPR News: 02-24-2026 6PM EST
“Announced price cuts for Ozempic and Wegovy starting 2027, reducing list prices to $675/month following disappointing trial results”
Morning Wire · Feb 24, 2026
Evening Wire: Cartel Pressure Continues & Mamdani’s Shovel Struggles | 2.24.26
“Announced plans to cut GLP-1 drug prices by up to 50% starting 2027 amid market competition”
Motley Fool Money · Feb 24, 2026
Party Like it’s 2027
“Pharmaceutical company in litigation with Hims & Hers over GLP-1 drug distribution and marketing”
Morning Brew Daily · Feb 24, 2026
Fictional Story Tanks Stock Market & The iPod Making a Comeback?
“Danish pharma company making Ozempic; stock plunged 14% after experimental obesity drug failed to match Eli Lilly's results in trials”
CNBC's "Fast Money" · Feb 23, 2026
Tariffs, Banks & Private Credit Jitters… And Crypto Below $65K 2/23/26
“Weight loss drug competitor down 16% on disappointing Cagrasema trial results, trading at five-year lows with zero value assigned to core business”
Dr. Bob Martin Show · Feb 23, 2026
Recharge Your Body Battery: Small Choices, Big Shifts in Everyday Health
“Mentioned as competitor in trillion-dollar weight loss drug market alongside Pfizer, Viking Therapeutics, and others”
Morning Brew Daily · Feb 20, 2026
Tariffs Ineffective Against US Trade Deficit? & Family Feud Over Reese’s Recipe
“Danish pharmaceutical company; U.S. imports of Wegovy contributed to unchanged trade deficit despite tariffs”
My First Million · Feb 16, 2026
Asking Scott Galloway 10 Questions We’re Not Allowed To Ask (unfiltered)
“GLP-1 drug manufacturer; Galloway proposed government RFP for billion doses to distribute free to rural households”
Today, Explained · Feb 13, 2026
Skinny and sad on GLP-1s
“Manufacturer of brand-name GLP-1 drugs (Ozempic, Wegovy); took legal action against telehealth companies offering compounded versions”
CNBC's "Fast Money" · Feb 6, 2026
Mini Correction or Fundamental Rethinking?… And Bitcoin Bounces Back After Plunge 2/6/26
“GLP-1 manufacturer with less than 20% patent cliff exposure; stock up after FDA action against compounded competitors.”
TBPN · Feb 6, 2026
Chip Bottleneck vs. Energy Bottleneck, Amazon’s $200B Capex, Big Tech Earnings | Doug O'Laughlin, Max Levchin, TJ Parker, Arsalan Tavakoli
“Launched Wegovy pill and criticized Hims for illegal drug compounding”
Prof G Markets · Feb 5, 2026
Google Doubles Down on Spending as AI Fear Returns
“GLP-1 competitor facing market share erosion (30-40% of injectable market); oral therapy at $150/month vs prior $300-500; stock down 18% post-earnings”
Mad Money w/ Jim Cramer · Feb 5, 2026
Mad Money w/ Jim Cramer 2/4/26
“GLP-1 market leader with Ozempic/Wegovy facing pricing pressure; CEO discussed pill launch advantages and high-dose semaglutide strategy”
CNBC's "Fast Money" · Feb 4, 2026
Alphabet Reports Results… And Pharma Stocks Diverge In Weight Loss Drug Race 2/4/26
“Weight loss drug competitor down 20% over two sessions; guiding 5-13% sales decline; facing Medicare/Medicaid reimbursement delays”
Stronger Weekly · Feb 4, 2026
How Cold Plunging Reduced My Stress and Anxiety (6-Month Results)
“GLP-1 drug manufacturer facing 3,000+ lawsuits alleging inadequate warnings about gastroparesis, intestinal blockages, and vision loss side effects”
The Dr. John Delony Show · Jan 28, 2026
I’m Afraid I’m Going to Cheat on My Husband
“Manufacturer of Zepbound (semaglutide), the GLP-1 medication discussed by caller Amy as transformative for weight management”
Global Security Briefing · Jan 28, 2026
Greenland: A Flashpoint in Transatlantic Relations
“Danish pharmaceutical company controlling 74% of global insulin supply, representing critical supply chain leverage point”
Habits and Hustle · Jan 27, 2026
Episode 523: Ashley Koff, RD: GLP-1, Weight Loss and the Mistakes That Create Rebound
“Manufacturer of semaglutide (Ozempic, Wegovy); discussed as original GLP-1 developer with research-driven dosing protocols”
All-In with Chamath, Jason, Sacks & Friedberg · Jan 24, 2026
Healthcare Needs Builders, Not Bureaucrats: Dr. Mehmet Oz Live from Davos
All-In with Chamath, Jason, Sacks & Friedberg · Jan 23, 2026
Inside America's AI Strategy: Infrastructure, Regulation, and Global Competition
We're Out of Time · Jan 20, 2026
The Future of Addiction Treatment Starts Here: GLP-1s Explained With Dr. Ken Spielvogel
“Manufacturer of Ozempic (semaglutide), the first GLP-1 medication discussed for addiction treatment applications”
Dr. Jockers Functional Nutrition · Jan 20, 2026
The Hunger Code: Reset Your Fat Thermostat To Reduce Cravings and Turn Up Fat Burning with Dr Jason Fung"
“Manufacturer of GLP-1 receptor agonists (Ozempic, Wegovy) discussed as evidence that hunger reduction, not calorie restriction, drives weight loss”
The Jamie Kern Lima Show · Jan 20, 2026
#1 Menopause Doctor Masterclass Pt 4: GLP1s, Losing Belly Fat + Live Longer & Stronger Now! Dr. Mary Claire Haver
“Manufacturer of GLP-1 medications; discussed regarding pricing negotiations and cost differences between US ($1,000/month) and UK ($100/month)”
TBPN · Jan 17, 2026
The Elon vs OpenAI Lawsuit and ads in ChatGPT | Diet TBPN
Huberman Lab · Jan 12, 2026
How to Overcome Addiction to Substances or Behaviors | Dr. Keith Humphreys
Something You Should Know · Jan 5, 2026
How Ozempic and Similar Weight Loss Drugs Really Work & The Story of Money
“Danish pharmaceutical company that developed GLP-1 drugs including Ozempic for diabetes and obesity treatment”
Short Wave · Dec 19, 2025
GLP-1 Pills Are On The Way. Here's What To Know
“Manufactures Ozempic and Wegovy injectables; developing semaglutide pill expected for FDA approval by end of year”
DarkHorse Podcast · Dec 17, 2025
Was Darwin wrong? The 305th Evolutionary Lens with Bret Weinstein and Heather Heying
“Pharmaceutical company behind Ozempic/GLP-1 drugs; discussed for undisclosed cardiac and neurological side effects”
Wait Wait... Don't Tell Me! · Nov 22, 2025
WWDTM: Niki Russ Federman and Josh Russ Tupper
“Pharmaceutical company that announced price reduction for weight loss drug Ozempic”
unPAUSED with Dr. Mary Claire Haver · Nov 18, 2025
GLP-1s and Midlife Metabolism Part 2: Dr. Rocio Salas Whalen Breaks Down the Science of Weight Loss and Menopause
“Manufacturer of semaglutide (Ozempic, Wegovy) and tirzepatide; discussed pricing, vial options, and lawsuits against compounding pharmacies”
unPAUSED with Dr. Mary Claire Haver · Nov 11, 2025
GLP-1s and Midlife Metabolism: Dr. Rocio Salas-Whalen Breaks Down the Science of Weight Loss and Menopause: Part 1
“Manufacturer of semaglutide (Ozempic, Wegovy) and tirzepatide, primary GLP-1 medications discussed throughout episode”
All-In with Chamath, Jason, Sacks & Friedberg · Nov 7, 2025
Does OpenAI Need a Bailout? Mamdani Wins, Socialism Rising, Filibuster Nuclear Option
“Announced GLP-1 pricing initiatives alongside Eli Lilly for affordability”
Decoded | Unlock The Secrets of Human Behavior, Emotion and Motivation · Jul 31, 2025
The Peptide Protocol That Reversed My Autoimmune Symptoms
“Pharmaceutical company that manufactures semaglutide (Ozempic/Wegovy) and terzapatide (Mounjaro); discussed regarding patent enforcement and compounding pharmacy expansion”
Maintenance Phase · Oct 10, 2023
Ozempic
“Danish pharmaceutical company manufacturing Ozempic and Wegovy; uses 'It's Bigger Than Me' campaign targeting Black communities to market GLP-1 drugs as disease treatment”